<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2737">
  <stage>Registered</stage>
  <submitdate>16/04/2010</submitdate>
  <approvaldate>16/04/2010</approvaldate>
  <nctid>NCT01106716</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia</studytitle>
    <scientifictitle>A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>KAI-1678-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Postherpetic Neuralgia</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo
Treatment: drugs - KAI-1678
Treatment: drugs - Lidocaine

Placebo Comparator: A1: Placebo - Placebo

Experimental: A2: KAI-1678 - Experimental

Active Comparator: A3: Lidocaine - Lidocaine


Treatment: drugs: Placebo
Placebo IV Infusion

Treatment: drugs: KAI-1678
KAI-1678 IV Infusion

Treatment: drugs: Lidocaine
Lidocaine

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The effect of KAI-1678 on mean change from baseline in pain intensity at 6 hours (PID 6). - Measurements are made using a qualified pain scale and the change from basline is calculated at 6 hours.</outcome>
      <timepoint>Day 1</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of KAI-1678 on the proportion of subjects achieving at least a 1 point improvement in pain intensity at 6 hours</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of KAI-1678 on patient global response to treatment</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of KAI-1678 on symptoms associated with PHN assessed by the Neuropathic Pain Scale (NPS)</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The number of adverse events as a measure of safety and tolerability of KAI-1678 - Frequency of adverse events on each study treatment</outcome>
      <timepoint>Two weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  diagnosis of PHN with pain for at least 3 months after segmental herpes zoster
             eruption

          -  pain score at least 4 on 11-point numerical rating scale (0-10)

          -  stable doses of analgesic medications for at least 1 month"</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  diagnosis of PHN with pain for at least 3 months after segmental herpes zoster
             eruption

          -  pain score at least 4 on 11-point numerical rating scale (0-10)

          -  stable doses of analgesic medications for at least 1 month"</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>23</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital> - Sydney</hospital>
    <postcode> - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>KAI Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Trident Clinical Research Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether KAI-1678 is effective in the treatment of
      postherpetic neuralgia pain</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01106716</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregory Bell, MD</name>
      <address>KAI Pharmaceuticals, Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>